Download PDF
Nuklearmedizin 1994; 33(05): 224-228
DOI: 10.1055/s-0038-1629759
Original Article
Schattauer GmbH

Accumulation of 99mTc-Glutathione in Head and Neck Tumors[*]

Akkumulation von 99m Tc-Glutathion in Kopf- und Halstumoren
M. T. Ercan
1   From the Departments of Nuclear Medicine and Otorhinolaryngology, Faculty of Medicine, Hacettepe University, Ankara, Turkey
,
T. Aras
1   From the Departments of Nuclear Medicine and Otorhinolaryngology, Faculty of Medicine, Hacettepe University, Ankara, Turkey
,
A. Aktaş
1   From the Departments of Nuclear Medicine and Otorhinolaryngology, Faculty of Medicine, Hacettepe University, Ankara, Turkey
,
S. Kaya
1   From the Departments of Nuclear Medicine and Otorhinolaryngology, Faculty of Medicine, Hacettepe University, Ankara, Turkey
,
C. F. Bekdik
1   From the Departments of Nuclear Medicine and Otorhinolaryngology, Faculty of Medicine, Hacettepe University, Ankara, Turkey
› Author Affiliations
Further Information

Publication History

Received: 23 February 1994

in revised form: 12 April 1994

Publication Date:
02 February 2018 (online)

    Permissions and Reprints

Summary

Glutathione labelled with 99mTc was used to study blood clearance and normal distribution in 3 healthy volunteers and in 10 patients with biopsy-proven tumors in the head and neck region. Static scintigrams were obtained at 1, 3, 6, and 24 h. ROIs over tumors and normal soft tissues were compared to obtain T/N ratios. In normal subjects blood clearance reached a plateau at 6 h; no radioactivity accumulation in the head and neck region was observed. Only the cardiac blood pool, the liver, the kidneys and the urinary bladder were evident. Excretion was via the kidneys. Malignant tumors and metastases were well visualized in 7 patients (true-positive), starting at 1 h. The mean T/N ratio was 2.69 ± 0.77. The best images were obtained at 3-6 h. 1 false-positive (granula-matous reaction), 1 false-negative (malignant epithelial tumor in the radix of tongue) and 1 true-negative (angiofibroma) results were obtained. 99mTc-GSH is a potential radiopharmaceutical for the scintigraphic visualization of head and neck tumors. Further clinical studies are warranted to show its sensitivity and accuracy.

Zusammenfassung

Mit 99mTc markiertes Glutathion wurde zur Bestimmung der Blutclearance und Normalverteilung bei 3 gesunden Freiwilligen und bei 10 Patienten mit bioptisch nachgewiesenen Tumoren im Kopf/Hals-Bereich verwendet. Statische Szintigramme wurden nach 1, 3, 6 und 24 h aufgenommen und ROIs über den Tumoren und normalem Weichteilgewebe verglichen, um T/N-Daten zu ermitteln. Bei den Probanden erreichte die Blutclearance nach 6 h ihr Plateau; eine Aktivitätsanreicherung im Kopf/Hals-Bereich wurde nicht beobachtet. Nur der kardiale Blutpool, die Leber, die Nieren und die Harnblase wurden dargestellt. Die Ausscheidung erfolgte über die Nieren. Bösartige Tumoren und Metastasen wurden bei 7 Patienten ab 1 h deutlich sichtbar (richtig-positiv); das durchschnittliche T/N-Verhältnis betrug 2,69 ± 0,77. Die besten Bilder wurden zwischen 3 und 6 h erhalten. Ein falsch-positives (granulomatöse Reaktion), ein falschnegatives (maligner Epitheltumor an der Zungenwurzel) und ein richtig-negatives (Angiofibrom) Ergebnis wurden registriert. 99mTc-GSA ist ein potentielles Radiopharmakon für die szintigraphische Darstellung von Kopf- und Hals-Tumoren. Weitere klinische Studien sind erforderlich, um die Sensitivität und Genauigkeit der Methode zu bestimmen.

Key words

99mTc glutathione - head and neck tumors - blood clearance

Schlüsselwörter

99mTc-Glutathion - Tumoren des Kopf/Hals-Bereichs - Blutclearance

* Part of this work was presented at the European Association of Nuclear Medicine Congress, 10-14 October, 1993, Lausanne, Switzerland


 

  • Literatur

  • 1 Cummings CW, Larson SM, Dobie RA. et al. Assessment of Cobalt 57 tagged bleomycin as a clinical aid in staging of head and neck carcinoma. Laryngoscope 1981; 91: 529-37.
    CrossrefPubMedGoogle Scholar
  • 2 Ercan MT, Bekdik CF, Sarizi T. 99nTc-Gluta-thione: Labelling and distribution in rats. Int J Appl Radiat Isot 1978; 29: 697-8.
    CrossrefPubMedGoogle Scholar
  • 3 Ercan MT, Aras T, Unlenen E. et al. 99mTc-citrate versus 67Ga-citrate for the scintigraphic visualization of inflammatory lesions. Nucl Med Biol 1993; 20: 881-7.
    CrossrefPubMedGoogle Scholar
  • 4 Ercan MT, Unlenen E. Accumulation of some small molecular weight complexes of 99mTc in experimental abscesses. Nucl Med Biol 1994; 21: 143-9.
    CrossrefPubMedGoogle Scholar
  • 5 Ercan MT, Unlenen E, Aktaş A. Techneti-um-99m glutathione for imaging inflammatory lesions. Nucl Med Commun 1994; 15: 533-9.
    CrossrefPubMedGoogle Scholar
  • 6 Fischman AJ, Pike MC, Kroon D. et al. Imaging focal sites of bacterial infection in rats with indium-III labelled chemotactic peptide analogs. J Nucl Med 1991; 32: 483-91.
    PubMedGoogle Scholar
  • 7 Goodwin DA, Meares CF, De Riemer LH. et al. Clinical studies with In-III BLEDTA, a tumor-imaging conjugate of Bleomycin with a bifunctional chelating agent. J Nucl Med 1981; 22: 787-92.
    PubMedGoogle Scholar
  • 8 Hoffer PB, Gottschalk A. Tumor scanning agents. Sem Nucl Med 1974; 4: 305-16.
    Google Scholar
  • 9 Kairemo KJA, Hopsu EVM. Imaging of pharnygeal and laryngeal carcinomas with Indium-III-labelled monoclonal anti-CEA antibodies. Laryngoscope 1990; 100: 1077-82.
    PubMedGoogle Scholar
  • 10 Kaplowitz N, Aw TY, Ookhtens M. The regulation of hepatic glutathione. Ann Rev Pharmacol Toxicol 1985; 25: 715-44.
    CrossrefPubMedGoogle Scholar
  • 11 Kashima HK, McKusick KA, Malmud LS, Wagner Jr HN. Gallium-67 scanning in patients with head and neck cancer. Laryngoscope 1974; 84: 1078-89.
    CrossrefPubMedGoogle Scholar
  • 12 Krenning EP, Bakker WH, Breeman WAP. et al. Localization of endocrine-related tumors with radioiodinated analogue of somatostatin. Lancet 1989; 1: 242-4.
    CrossrefPubMedGoogle Scholar
  • 13 Lavender JP, Loew J, Barker JR, Burn IJ, Chaudri MA. Gallium-67 citrate scanning in neoplastic and inflammatory lesions. Br J Radiol 1971; 44: 361-6.
    CrossrefPubMedGoogle Scholar
  • 14 Meister A, Anderson ME. Glutathione. Ann Rev Biochem 1983; 52: 711-60.
    CrossrefPubMedGoogle Scholar
  • 15 Mori T, Hamamoko K, Onoyama Y. et al. Tumor imaging after administration of 99mTc-labelled bleomycin. J Nucl Med 1975; 16: 414-22.
    PubMedGoogle Scholar
  • 16 Muller SP, Paas M, Reiners C. ROC-Analyse der Tumorerkennbarkeit mit 201T1 (I) chloride und “mTc (I) hexakis (2-methoxy-2-isobutylisonitrile). Nucl-Med 1994; 33: 15-23.
    Google Scholar
  • 17 Novi AM. Regression of aflatoxin B,-in-creased hepatocellular carcinomas by reduced glutathione. Science 1981; 212: 541-2.
    CrossrefPubMedGoogle Scholar
  • 18 Reed DJ. Regulation of reductive processes by glutathione. Biochem Pharmacol 1986; 35: 7-13.
    CrossrefPubMedGoogle Scholar
  • 19 Reed DJ. Glutathione: toxicological implications. Ann Rev Pharmacol Toxicol 1990; 30: 603-31.
    CrossrefPubMedGoogle Scholar
  • 20 Reed DJ, Fariss MW. Glutathione depletion and susceptibility. Pharmacol Rev 1984; 36: 25-33s.
    Google Scholar
  • 21 Teates C, Preston DF, Boyd CM. Gallium-67 citrate imaging in head and neck tumors: report of cooperative group. J Nucl Med 1980; 21: 622-7.
    PubMedGoogle Scholar
  • 22 Tzen KY, Oster ZH, Wagner HN, Tsan MF. Role of iron binding proteins and enhanced vascular permeability in the accumulation of gallium-67. J Nucl Med 1980; 21: 31-5.
    PubMedGoogle Scholar
  • 23 Watkinson JC, Lazarus CR, Mistry R. et al. Technetium-99m (V) dimercaptosuccinic acid uptake in patients with head and neck squamous carcinoma: experience in imaging. J Nucl Med 1989; 30: 174-80.
    PubMedGoogle Scholar